Tag - SAGE

Developments

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage Therapeutics (NASDAQ:SAGE) announced its Phase 2 SURVEYOR study has met its primary endpoint showing a significant difference in HD-Cognitive Assessment Battery composite scores at baseline between healthy...

June 11, 2024

Developments

Sage in reorganization to support launch of ZURZUVAE, advance pipeline

Sage Therapeutics (NASDAQ:SAGE) plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with...

August 31, 2023

Tag - SAGE

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage in reorganization to support launch of ZURZUVAE, advance pipeline

General

More